Skip to main content

ADPT

Stock
Health Care
Biotechnology

Performance overview

ADPT Price
Price Chart

Forward-looking statistics

Beta
2.02
Risk
81.88%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Company info

SectorHealth Care
IndustryBiotechnology
Employees770
Market cap$532.0M

Fundamentals

Enterprise value$1.8B
Revenue$189.5M
Revenue per employee—
Profit margin-74.84%
Debt to equity115.90

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.95
Dividend per share—
Revenue per share$1.28
Avg trading volume (30 day)$21M
Avg trading volume (10 day)$35M
Put-call ratio—

Macro factor sensitivity

Growth+3.1
Credit+23.9
Liquidity-10.0
Inflation-3.0
Commodities+2.2
Interest Rates-3.6

Valuation

Dividend yield0.00%
PEG Ratio-12.55
Price to sales9.46
P/E Ratio-12.55
Enterprise Value to Revenue9.48
Price to book9.42

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend day—

News

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Zacks Investment Research (July 4, 2025)
Top 3 Health Care Stocks That May Collapse This Quarter

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga (December 11, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free